Eosinophilia Therapeutics Market on Course for 6% CAGR Growth by 2033

According to Future Market Insights, the eosinophilia therapies market will develop between 2023 and 2033 at a compound annual growth rate (CAGR) of 6%. By 2033, it is projected that the global market for eosinophilia therapies would be valued US$ 739.62 million. The market is anticipated to expand as a result of increased investment in healthcare facilities, increased research and development (RD) for new medications and treatments targeted to specific diseases, increased frequency with which regulatory bodies are approving special designations, and the rise in autoimmune diseases like asthma.

The growth of the market is being fueled by several factors, including an increasing number of regulatory approvals in developed countries. Other factors include rising investment in healthcare infrastructure, growth in demand for biologic therapies, an increase in demand for novel disease-specific treatments, higher personal disposable income, and increased product launches. These factors are expected to provide ample growth opportunities in the market.

Unleash Your Potential: Experience Unparalleled Excellence with Our Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16648

Another trend shaping the Eosinophilia Therapeutics Market is the increasing demand for biologic therapies. Biologic therapies are a class of drugs that are derived from living organisms and are used to treat a wide range of autoimmune and inflammatory disorders. These therapies are becoming increasingly popular due to their ability to target specific parts of the immune system, providing more effective treatments to patients with eosinophilia and other autoimmune disorders.

Key Takeaways:

The Eosinophilia therapeutics market is expected to grow at a value of 6% CAGR in the forecast period 2023-2033.
By distribution channel, hospital pharmacies are expected to procure 45% market share for eosinophilia therapeutics market.
North America is expected to procure 43% market share for eosinophilia therapeutics market.
Europe is expected to possess 38% market share for eosinophilia therapeutics market.

“Increase in research and development activities along with growing awareness regarding the ailment is spurring the growth of Eosinophilia therapeutics market.” states an FMI analyst

Competitive Landscape

Key players in the eosinophilia therapeutics market are GlaxoSmithKline plc, Sanofi, Takeda Pharmaceutical Company Limited, Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Merck Co., Inc, Eli Lilly and Company, AstraZeneca, Bayer AG, Gilead Sciences, Inc, Regeneron Pharmaceuticals, Inc., Cipla Inc.

In 2021, Takeda announced the results of a Phase 3 clinical trial for its drug reslizumab for the treatment of eosinophilic asthma. The results showed that the drug improved lung function and reduced the number of severe asthma attacks in patients with the condition.
Roche, another key player in the eosinophilia therapeutics market has also been working on the development of a new therapy for the treatment of EGIDs. The therapy, called risankizumab, is a biologic drug that specifically targets the cytokine IL-23, which is involved in the development of eosinophilic inflammation. The drug is currently in late-stage clinical development.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Eosinophilia therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug Class (Corticosteroids, Immunosuppressant, Monoclonal Antibody) Type Blood Eosinophilia, Tissue Eosinophilia Route of Administration (Oral, Intravenous) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)

Key Segments:

Drug Class: